BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pesch B, Taeger D, Johnen G, Gawrych K, Bonberg N, Schwentner C, Wellhäußer H, Kluckert M, Leng G, Nasterlack M. Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. Int Arch Occup Environ Health. 2014;87:715-724. [PMID: 24129706 DOI: 10.1007/s00420-013-0916-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Dutheil F, Rouanet L, Mulliez A, Naughton G, Fontana L, Druet-Cabanac M, Moustafa F, Chamoux A. Urine cytology screening of French workers exposed to occupational urinary tract carcinogens: a prospective cohort study over a 20-year period. BMJ Open 2017;7:e016238. [PMID: 28939575 DOI: 10.1136/bmjopen-2017-016238] [Reference Citation Analysis]
2 Jalilian H, Ziaei M, Weiderpass E, Rueegg CS, Khosravi Y, Kjaerheim K. Cancer incidence and mortality among firefighters. Int J Cancer 2019;145:2639-46. [PMID: 30737784 DOI: 10.1002/ijc.32199] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
3 Behrens T, Stenzl A, Brüning T. Factors Influencing False-positive Results for Nuclear Matrix Protein 22. European Urology 2014;66:970-2. [DOI: 10.1016/j.eururo.2014.06.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
4 Krauß SD, Yosef HK, Lechtonen T, Jütte H, Tannapfel A, Käfferlein HU, Brüning T, Roghmann F, Noldus J, El-mashtoly SF, Gerwert K, Mosig A. Integrating spatial, morphological, and textural information for improved cell type differentiation using Raman microscopy: Integrating spatial, morphological, and textural information for improved cell type differentiation using Raman microscopy. Journal of Chemometrics 2018;32:e2973. [DOI: 10.1002/cem.2973] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
5 Schmitz-dräger C, Bonberg N, Pesch B, Todenhöfer T, Sahin S, Behrens T, Brüning T, Schmitz-dräger BJ. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non–muscle-invasive bladder cancer?—An International Bladder Cancer Network project. Urologic Oncology: Seminars and Original Investigations 2016;34:452-9. [DOI: 10.1016/j.urolonc.2016.06.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
6 Hudolin T, Kastelan Z, El-Saleh A, Bakula M, Coric M, Kes P, Tomas D, Basic-Jukic N. Bone morphogenic proteins-2, -4, -6 and 7 in non-muscle invasive bladder cancer. Oncol Lett 2020;19:1291-7. [PMID: 31966059 DOI: 10.3892/ol.2019.11218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Bonberg N, Pesch B, Behrens T, Johnen G, Taeger D, Gawrych K, Schwentner C, Wellhäußer H, Kluckert M, Leng G, Nasterlack M, Oberlinner C, Stenzl A, Brüning T. Chromosomal alterations in exfoliated urothelial cells from bladder cancer cases and healthy men: a prospective screening study. BMC Cancer 2014;14:854. [PMID: 25412927 DOI: 10.1186/1471-2407-14-854] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
8 Clin B, Pairon JC; "RecoCancerProf" Working Group. Medical follow-up for workers exposed to bladder carcinogens: the French evidence-based and pragmatic statement. BMC Public Health 2014;14:1155. [PMID: 25377503 DOI: 10.1186/1471-2458-14-1155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Huang Y, Jin X, Yan S, Cong H, Tao Z. Size Effect of Multifarenes on Host-Guest Interactions with Naphthylamines and Naphthols. ChemistrySelect 2018;3:4705-11. [DOI: 10.1002/slct.201800812] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
10 Benderska-Söder N, Hovanec J, Pesch B, Goebell PJ, Roghmann F, Noldus J, Rabinovich J, Wichert K, Gleichenhagen J, Käfferlein HU, Köhler CU, Johnen G, Kernig K, Hakenberg O, Jahn D, Todenhöfer T, Stenzl A, Gleissner J, Gerwert K, El-Mashtoly S, Behrens T, Brüning T, Schmitz-Dräger BJ. Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial. Urol Oncol 2020;38:886-95. [PMID: 32199755 DOI: 10.1016/j.urolonc.2020.01.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
11 Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Seisen T, Soukup V, Sylvester RJ. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol 2021:S0302-2838(21)01978-3. [PMID: 34511303 DOI: 10.1016/j.eururo.2021.08.010] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
12 Tsai MM, Wang CS, Tsai CY, Chi HC, Tseng YH, Lin KH. Potential prognostic, diagnostic and therapeutic markers for human gastric cancer. World J Gastroenterol 2014; 20(38): 13791-13803 [PMID: 25320517 DOI: 10.3748/wjg.v20.i38.13791] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
13 Yosef HK, Krauß SD, Lechtonen T, Jütte H, Tannapfel A, Käfferlein HU, Brüning T, Roghmann F, Noldus J, Mosig A, El-Mashtoly SF, Gerwert K. Noninvasive Diagnosis of High-Grade Urothelial Carcinoma in Urine by Raman Spectral Imaging. Anal Chem 2017;89:6893-9. [PMID: 28541036 DOI: 10.1021/acs.analchem.7b01403] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
14 Soria F, D’andrea D, Pohar K, Shariat SF, Lotan Y. Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice? Current Opinion in Urology 2018;28:577-83. [DOI: 10.1097/mou.0000000000000545] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
15 Nagai T, Naiki T, Etani T, Iida K, Noda Y, Shimizu N, Isobe T, Nozaki S, Okamura T, Ando R, Kawai N, Yasui T. UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative review and future perspectives. Transl Androl Urol 2021;10:1908-17. [PMID: 33968678 DOI: 10.21037/tau-20-1207] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Gleichenhagen J, Arndt C, Casjens S, Meinig C, Gerullis H, Raiko I, Brüning T, Ecke T, Johnen G. Evaluation of a New Survivin ELISA and UBC® Rapid for the Detection of Bladder Cancer in Urine. Int J Mol Sci 2018;19:E226. [PMID: 29324722 DOI: 10.3390/ijms19010226] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
17 Zi H, He SH, Leng XY, Xu XF, Huang Q, Weng H, Zhu C, Li LY, Gu JM, Li XH, Ming DJ, Li XD, Yuan S, Wang XH, He DL, Zeng XT. Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990-2019. Mil Med Res 2021;8:60. [PMID: 34819142 DOI: 10.1186/s40779-021-00354-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Deininger S, Törzsök P, Oswald D, Lusuardi L. Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy-A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin. Cancers (Basel) 2021;13:3206. [PMID: 34206980 DOI: 10.3390/cancers13133206] [Reference Citation Analysis]
19 Aguilar-Madrid G, Pesch B, Calderón-Aranda ES, Burek K, Jiménez-Ramírez C, Juárez-Pérez CA, Ochoa-Vázquez MD, Torre-Bouscoulet L, Acosta-Saavedra LC, Sada-Ovalle I, García-Figueroa J, Alvarado-Cabrero I, Castillo-González P, Báez-Saldaña AR, Pérez-Padilla JR, Osnaya-Juárez J, Rivera-Rosales RM, García-Bazán EM, Bautista-Aragón YL, Lazcano-Hernandez E, Munguía-Canales DA, Argote-Greene LM, Taeger D, Weber DG, Casjens S, Raiko I, Brüning T, Johnen G. Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population. Int J Med Sci 2018;15:883-91. [PMID: 30008600 DOI: 10.7150/ijms.23939] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
20 Liu D, Qiu X, Xiong X, Chen X, Pan F. Current updates on the role of reactive oxygen species in bladder cancer pathogenesis and therapeutics. Clin Transl Oncol 2020;22:1687-97. [PMID: 32189139 DOI: 10.1007/s12094-020-02330-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
21 Bie Z, Lu W, Zhu Y, Chen Y, Ren H, Ji L. Rapid determination of six carcinogenic primary aromatic amines in mainstream cigarette smoke by two-dimensional online solid phase extraction combined with liquid chromatography tandem mass spectrometry. Journal of Chromatography A 2017;1482:39-47. [DOI: 10.1016/j.chroma.2016.12.060] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
22 Hosen MI, Sheikh M, Zvereva M, Scelo G, Forey N, Durand G, Voegele C, Poustchi H, Khoshnia M, Roshandel G, Sotoudeh M, Nikmanesh A, Etemadi A, Avogbe PH, Chopard P, Delhomme TM, Foll M, Manel A, Vian E, Weiderpass E, Kamangar F, Boffetta P, Pharaoh PD, Dawsey SM, Abnet CC, Brennan P, McKay J, Malekzadeh R, Calvez-Kelm FL. Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study. EBioMedicine 2020;53:102643. [PMID: 32081602 DOI: 10.1016/j.ebiom.2020.102643] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
23 Burger M, Schwaibold H, Goebell P, Grimm M. Nichtinvasives Harnblasenkarzinom. Onkologe 2018;24:23-31. [DOI: 10.1007/s00761-017-0314-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Johnen G, Burek K, Raiko I, Wichert K, Pesch B, Weber DG, Lehnert M, Casjens S, Hagemeyer O, Taeger D, Brüning T; MoMar Study Group. Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers. Sci Rep 2018;8:14321. [PMID: 30254313 DOI: 10.1038/s41598-018-32315-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]